NCT04756297 is a clinical trial in Bronchopulmonary Dysplasia (BPD), sponsored by Adel Mohamed.

Who is sponsoring NCT04756297?

NCT04756297 is sponsored by Adel Mohamed.

What condition does NCT04756297 study?

NCT04756297 studies Bronchopulmonary Dysplasia (BPD).

Is NCT04756297 still recruiting?

NCT04756297 is currently completed. Last updated 1 April 2021.

Last reviewed 2021-04-01 · How we verify

NCT04756297

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Lung Ultrasound for Prediction of Bronchopulmonary Dysplasia

Completed Last updated 1 April 2021

What this trial tests

trial in Bronchopulmonary Dysplasia (BPD) in 152 participants. Completed in 25 February 2021.

Timeline

1 July 2019

Primary endpoint
25 February 2021

25 February 2021

Quick facts

Lead sponsor	Adel Mohamed
Status	Completed
Study type	OBSERVATIONAL
Enrollment	152
Start date	1 July 2019
Primary completion	25 February 2021
Estimated completion	25 February 2021
Sites	2 locations across Canada

Conditions studied

Bronchopulmonary Dysplasia (BPD) — all drugs for Bronchopulmonary Dysplasia (BPD) →

Sponsor

Adel Mohamed

Who can join

Eligibility, any sex, with Bronchopulmonary Dysplasia (BPD). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Extreme preterm infants (GA ≤ 28+6 weeks) are at high risk for bronchopulmonary dysplasia (BPD) that has been associated with significant long-term impairment. Lung ultrasound score (LUSs) has the potential to early identify infants at high risk of developing BPD who may benefit from early intervention. Aim: To assess if LUS score can be utilized to predict the development of BPD in infants born at ≤ 28+6 weeks, early in their postnatal course, when the disease is likely to be most amenable to therapeutic intervention.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Bronchopulmonary Dysplasia (BPD)

Currently open trials in the same condition.

NCT07101640 — PK, Safety and Preliminary Efficacy Study of Montelukast in Critically Ill Infants With Developing Bronchopulmonary Dysp · Phase 1, PHASE2 · recruiting
NCT07273643 — Characterization of Extracellular Vesicles From the Cord Blood of Extremely Preterm New Borns and Their Correlation With · recruiting
NCT07120971 — Metformin for Premature Infants With Bronchopulmonary Dysplasia · EARLY_PHASE1 · recruiting
NCT04545866 — The Budesonide in Babies (BiB) Trial · Phase 3 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04756297 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Adel Mohamed
Last refreshed: 1 April 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04756297.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing